• Guo-Yao Dai and Ye-Hua Zhu.
• Department of Pharmacy, General Hospital of Eastern Theater Command, Nanjing, Jiangsu Province, China.
• Medicine (Baltimore). 2022 Apr 1; 101 (13): e29148e29148.

BackgroundEssential hypertension has been regarded a significant risk factor for cardiovascular disease across the globe, and a significant escapable causation of early death as well as morbidity in the U.S. When angiotensin II receptor blockers and calcium channel blockers are used to treat essential hypertension, most patients will have inadequate blood pressure management. As a result, including a diuretic in the regimen is necessary. The current study's aim is to investigate the effectiveness as well as safety of levamlodipine besylate combination therapy in treating essential hypertension at varying degrees of severity.MethodsIn establishing the effectiveness and safety of the mix of levamlodipine besylate and dihydropyridine for essential hypertension, the authors will conduct a systematic review and, where applicable, a meta-analysis of randomized controlled clinical trials. A total of 8 electronic databases will be used in the search, including 4 English databases (PubMed, Web of Science, EMBASE, and Cochrane Library) and 4 Chinese databases (China National Knowledge Infrastructure, Chinese BioMedical Literature database, Chinese Scientific Journal database, and WanFang database). All articles published in the databases will be considered between their inception and January 18, 2022. Only articles published in English or Mandarin Chinese will be picked. A group of writers will independently evaluate each reference to see if it is eligible and whether there are any duplicates. The same authors will do data extraction for all eligible studies and use the Cochrane risk of bias tool to evaluate the risk of bias in the trials chosen for inclusion.ResultsThe analysis will evaluate the efficiency and level of safeness of levamlodipine besylate combined treatment for essential hypertension.ConclusionsOur systematic review will offer evidence for judging whether levamlodipine besylate combination therapy can be considered an effective intercession for essential hypertension.Ethics And DisseminationEthical approval will not be required as no original data will be collected as part of this review.Registration NumberDOI 10.17605/OSF.IO/H8ZR2.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

13 keywords...

hide…